Adverum Net Debt from 2010 to 2024

ADVM Stock  USD 6.64  0.19  2.95%   
Adverum Biotechnologies Net Debt yearly trend continues to be very stable with very little volatility. Net Debt is likely to grow to about 37.8 K this year. Net Debt is the total debt of Adverum Biotechnologies minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals
 
Net Debt  
First Reported
2013-12-31
Previous Quarter
-53.4 M
Current Value
-19.6 M
Quarterly Volatility
98.7 M
 
Yuan Drop
 
Covid
Check Adverum Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adverum Biotechnologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.9 M, Interest Expense of 3.2 M or Selling General Administrative of 31.8 M, as well as many indicators such as Price To Sales Ratio of 23.04, Dividend Yield of 0.0 or PTB Ratio of 0.96. Adverum financial statements analysis is a perfect complement when working with Adverum Biotechnologies Valuation or Volatility modules.
  
Check out the analysis of Adverum Biotechnologies Correlation against competitors.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.

Latest Adverum Biotechnologies' Net Debt Growth Pattern

Below is the plot of the Net Debt of Adverum Biotechnologies over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Adverum Biotechnologies' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adverum Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
Net Debt10 Years Trend
Pretty Stable
   Net Debt   
       Timeline  

Adverum Net Debt Regression Statistics

Arithmetic Mean(54,914,880)
Geometric Mean5,983,510
Coefficient Of Variation(178.04)
Mean Deviation78,779,680
Median(564,000)
Standard Deviation97,773,091
Sample Variance9559.6T
Range327.9M
R-Value0.22
Mean Square Error9780.1T
R-Squared0.05
Significance0.42
Slope4,889,038
Total Sum of Squares133834.1T

Adverum Net Debt History

202437.8 K
202336 K
202238.4 M
202168.8 M
2020-31.7 M
2019-33.6 M
2018-154.6 M

Other Fundumenentals of Adverum Biotechnologies

Adverum Biotechnologies Net Debt component correlations

0.94-0.06-0.610.56-0.520.460.650.940.310.840.460.820.75-0.640.280.740.390.560.510.6
0.94-0.27-0.330.48-0.470.40.421.0-0.010.820.60.820.57-0.44-0.010.550.260.710.680.35
-0.06-0.27-0.40.150.310.210.48-0.280.410.030.080.280.36-0.360.360.390.230.080.030.52
-0.61-0.33-0.4-0.570.34-0.2-0.84-0.36-0.91-0.460.16-0.4-0.90.83-0.81-0.93-0.590.090.16-0.92
0.560.480.15-0.57-0.32-0.080.470.490.370.360.250.50.6-0.670.310.670.490.170.110.45
-0.52-0.470.310.34-0.32-0.2-0.37-0.48-0.27-0.35-0.07-0.18-0.370.35-0.21-0.350.12-0.08-0.05-0.33
0.460.40.21-0.2-0.08-0.20.510.39-0.050.370.610.450.33-0.19-0.180.290.00.380.360.28
0.650.420.48-0.840.47-0.370.510.430.690.40.10.530.89-0.720.640.880.370.140.060.86
0.941.0-0.28-0.360.49-0.480.390.430.030.820.560.810.58-0.450.020.560.280.680.650.37
0.31-0.010.41-0.910.37-0.27-0.050.690.030.2-0.490.070.7-0.660.940.720.44-0.38-0.440.84
0.840.820.03-0.460.36-0.350.370.40.820.20.530.840.62-0.530.140.610.220.70.680.58
0.460.60.080.160.25-0.070.610.10.56-0.490.530.710.11-0.09-0.570.11-0.070.820.81-0.02
0.820.820.28-0.40.5-0.180.450.530.810.070.840.710.65-0.540.060.640.360.840.80.53
0.750.570.36-0.90.6-0.370.330.890.580.70.620.110.65-0.820.630.990.510.240.170.92
-0.64-0.44-0.360.83-0.670.35-0.19-0.72-0.45-0.66-0.53-0.09-0.54-0.82-0.49-0.86-0.45-0.14-0.07-0.77
0.28-0.010.36-0.810.31-0.21-0.180.640.020.940.14-0.570.060.63-0.490.630.41-0.34-0.40.75
0.740.550.39-0.930.67-0.350.290.880.560.720.610.110.640.99-0.860.630.560.210.140.92
0.390.260.23-0.590.490.120.00.370.280.440.22-0.070.360.51-0.450.410.56-0.08-0.110.41
0.560.710.080.090.17-0.080.380.140.68-0.380.70.820.840.24-0.14-0.340.21-0.081.00.12
0.510.680.030.160.11-0.050.360.060.65-0.440.680.810.80.17-0.07-0.40.14-0.111.00.05
0.60.350.52-0.920.45-0.330.280.860.370.840.58-0.020.530.92-0.770.750.920.410.120.05
Click cells to compare fundamentals

About Adverum Biotechnologies Financial Statements

Adverum Biotechnologies investors utilize fundamental indicators, such as Net Debt, to predict how Adverum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Debt36 K37.8 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:
Check out the analysis of Adverum Biotechnologies Correlation against competitors.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.95)
Revenue Per Share
0.059
Quarterly Revenue Growth
(0.70)
Return On Assets
(0.30)
Return On Equity
(0.76)
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.